Defining the value of magnetic resonance imaging in prostate brachytherapy using time-driven activity-based costing

被引:12
作者
Thaker, Nikhil G. [1 ]
Orio, Peter F. [2 ]
Potters, Louis [3 ]
机构
[1] US Oncol Network, Arizona Oncol, Dept Radiat Oncol, 2625 N Craycroft,Suite 100, Tucson, AZ 85712 USA
[2] Milford Reg Med Ctr, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA
[3] North Shore LIJ Hlth Syst, Dept Radiat Med, New Hyde Pk, NY USA
关键词
Value; Value-based healthcare delivery; Brachytherapy; Magnetic resonance imaging; Time-driven activity-based costing; UNITED-STATES; CANCER; CARE;
D O I
10.1016/j.brachy.2016.11.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Magnetic resonance imaging (MRI) simulation and planning for prostate brachytherapy (PBT) may deliver potential clinical benefits but at an unknown cost to the provider and healthcare system. Time-driven activity-based costing (TDABC) is an innovative bottom-up costing tool in healthcare that can be used to measure the actual consumption of resources required over the full cycle of care. TDABC analysis was conducted to compare patient-level costs for an MRI-based versus traditional PBT workflow. TDABC cost was only 1% higher for the MRI-based workflow, and utilization of MRI allowed for cost shifting from other imaging modalities, such as CT and ultrasound, to MRI during the PBT process. Future initiatives will be required to follow the costs of care over longer periods of time to determine if improvements in outcomes and toxicities with an MRI-based approach lead to lower resource utilization and spending over the long-term. Understanding provider costs will become important as healthcare reform transitions to value-based purchasing and other alternative payment models. (C) 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:665 / 671
页数:7
相关论文
共 28 条
  • [1] [Anonymous], 2011, HARV BUS REV
  • [2] Proton Beam Radiation Therapy for Head and Neck Malignancies
    Frank, Steven J.
    Selek, Ugur
    [J]. CURRENT ONCOLOGY REPORTS, 2010, 12 (03) : 202 - 207
  • [3] Kaplan R, 2015, HARV BUSINESS REV
  • [4] Kaplan Robert S, 2014, Healthc Financ Manage, V68, P76
  • [5] Kaplan RS, 2011, HARVARD BUS REV, V89, P46
  • [6] Kaplan RS, 2011, HARV BUS REV, V54, P56
  • [7] Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer
    Laviana, Aaron A.
    Ilg, Annette M.
    Veruttipong, Darlene
    Tan, Hung-Jui
    Burke, Michael A.
    Niedzwiecki, Douglas R.
    Kupelian, Patrick A.
    King, Chris R.
    Steinberg, Michael L.
    Kundavaram, Chandan R.
    Kamrava, Mitchell
    Kaplan, Alan L.
    Moriarity, Andrew K.
    Hsu, William
    Margolis, Daniel J. A.
    Hu, Jim C.
    Saigal, Christopher S.
    [J]. CANCER, 2016, 122 (03) : 447 - 455
  • [8] Stereotactic Body Radiotherapy for Lung Cancer How Much Does it Really Cost?
    Lievens, Yolande
    Obyn, Caroline
    Mertens, Anne-Sophie
    Van Halewyck, Dries
    Hulstaert, Frank
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 454 - 461
  • [9] Declining use of brachytherapy for the treatment of prostate cancer
    Mahmood, Usama
    Pugh, Thomas
    Frank, Steven
    Levy, Lawrence
    Walker, Gary
    Hague, Waqar
    Koshy, Matthew
    Graber, William
    Swanson, David
    Hoffman, Karen
    Kuban, Deborah
    Lee, Andrew
    [J]. BRACHYTHERAPY, 2014, 13 (02) : 157 - 162
  • [10] Projections of the Cost of Cancer Care in the United States: 2010-2020
    Mariotto, Angela B.
    Yabroff, K. Robin
    Shao, Yongwu
    Feuer, Eric J.
    Brown, Martin L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (02): : 117 - 128